Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia

Condition(s) studied

Study summary

Heparin-induced thrombocytopenia (HIT) is a rare but serious immune complication of heparin exposure that paradoxically increases the risk of thrombosis. In patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), heparin is essential to prevent circuit clotting, yet contraindicated in HIT. Available alternatives carry significant limitations. Cangrelor, an intravenous reversible P2Y12 inhibitor, has shown promise in case reports and small series in this context, but no multicenter study exists. CATCH-IT is a multicenter retrospective observational study conducted across 11 French cardiac surgery centers, aiming to describe the safety and efficacy of cangrelor combined with heparin during CPB in confirmed HIT patients, by estimating the incidence of major bleeding and thrombotic events within 7 days after surgery.

Eligibility

Primary outcome measure(s)

• Incidence of major hemorrhagic and/or thrombotic events — 7 days postoperatively
  Proportion of patients experiencing at least one major hemorrhagic event (BARC grade ≥3, including hemoglobin drop ≥3 g/dL, red blood cell transfusion attributed to bleeding, need for interventional procedure, hemorrhagic shock, or documented intracranial hemorrhage) and/or thrombotic complication (imaging-confirmed ischemic stroke, acute mesenteric ischemia requiring surgery, acute limb ischemia, or vascular thrombosis) within 7 days after surgery.

Trial sites (1)

More Société Française d'Anesthésie et de Réanimation trials in France

Other trials for the same condition